Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 3/20 | 0.35 |
| ▸ | PGD | P52209 | 2/20 | 0.34 |
| ▸ | P2RY10 | O00398 | 4/20 | 0.33 |
| ▸ | GPR174 | Q9BXC1 | 3/20 | 0.33 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.33 |
| ▸ | PGK1 | P00558 | 1/20 | 0.33 |
| ▸ | PGK2 | P07205 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MPI | P34949 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 3/20 | 0.31 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7159089 | 0.89 | MAPK1 (0.40) | LAP3PGDP2RY10GPR174GPR34 | |
| SCHEMBL28584705 | 0.84 | ANPEP (0.37) | LAP3PGDANPEPERAP1 | |
| SCHEMBL23387514 | 0.78 | PGK1 (0.33) | LAP3PGDP2RY10GPR174GPR34 | |
| SCHEMBL27845283 | 0.77 | SMN1; SMN2 (0.41) | PGDP2RY10GPR174GPR34PGK1 | |
| SCHEMBL10760222 | 0.77 | HSD17B10 (0.50) | P2RY10GPR174GPR34HSD17B10 | |
| SCHEMBL3340733 | 0.77 | — | — | |
| SCHEMBL1079057 | 0.77 | — | — | |
| SCHEMBL3344507 | 0.77 | — | — | |
| SCHEMBL7157943 | 0.74 | TSHR (0.41) | LAP3PGDPGK1PGK2MAPK1 | |
| SCHEMBL269622 | 0.74 | CYP3A4 (0.38) | LAP3PGK1PGK2ANPEPERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329515-B2 | Solid support for the synthesis of 3′-amino oligonucleotides | SIGMA-ALDRICH CO. (US) | 2008-02-12 | — | — | US | disclosed |
| US-20040220397-A1 | Solid support for the synthesis of 3'-amino oligonucleotides | PROLIGO LLC (US) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220397-A1 | Solid support for the synthesis of 3'-amino oligonucleotides | PCNA, DERA, RNGTT | LAP3 1061/4885PGD 1546/4885P2RY10 4110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.